Pfizer Inc. (NYSE:PFE) – Research analysts at Truist Securiti decreased their Q4 2021 earnings per share estimates for Pfizer in a report issued on Tuesday, November 23rd. Truist Securiti analyst R. Karnauskas now anticipates that the biopharmaceutical company will post earnings per share of $0.83 for the quarter, down from their previous forecast of $0.84. Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.26. The company had revenue of $24.09 billion for the quarter, compared to analyst estimates of $22.82 billion. Pfizer had a return on equity of 31.66% and a net margin of 27.66%. The business’s revenue was up 134.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.72 earnings per share.
Several other equities research analysts also recently issued reports on PFE. JPMorgan Chase & Co. set a $42.00 price target on Pfizer in a report on Friday, November 5th. Benchmark increased their target price on Pfizer from $29.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 5th. The Goldman Sachs Group set a $48.00 price objective on Pfizer in a research note on Thursday, July 29th. Cantor Fitzgerald restated a “buy” rating and set a $60.00 price objective on shares of Pfizer in a research note on Friday, November 5th. Finally, Independent Research raised Pfizer to a “buy” rating and set a $53.00 target price on the stock in a report on Thursday, November 11th. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $49.00.
NYSE PFE opened at $50.89 on Thursday. The stock has a 50-day simple moving average of $45.01 and a 200 day simple moving average of $43.27. The company has a market capitalization of $285.64 billion, a PE ratio of 15.15, a P/E/G ratio of 1.16 and a beta of 0.72. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. Pfizer has a 12 month low of $33.36 and a 12 month high of $52.83.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 6th. Investors of record on Friday, November 5th will be paid a $0.39 dividend. The ex-dividend date is Thursday, November 4th. This represents a $1.56 annualized dividend and a yield of 3.07%. Pfizer’s payout ratio is 46.43%.
In other Pfizer news, insider John D. Young sold 150,000 shares of the business’s stock in a transaction on Thursday, November 11th. The shares were sold at an average price of $50.06, for a total transaction of $7,509,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Patten Group Inc. increased its holdings in shares of Pfizer by 1.9% in the third quarter. Patten Group Inc. now owns 11,113 shares of the biopharmaceutical company’s stock worth $478,000 after purchasing an additional 206 shares during the period. Castle Rock Wealth Management LLC increased its stake in Pfizer by 3.8% in the second quarter. Castle Rock Wealth Management LLC now owns 5,756 shares of the biopharmaceutical company’s stock valued at $277,000 after acquiring an additional 212 shares during the last quarter. Retirement Group LLC increased its stake in Pfizer by 7.4% in the third quarter. Retirement Group LLC now owns 3,196 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 220 shares during the last quarter. Tempus Wealth Planning LLC increased its stake in Pfizer by 0.6% in the third quarter. Tempus Wealth Planning LLC now owns 39,067 shares of the biopharmaceutical company’s stock valued at $1,680,000 after acquiring an additional 226 shares during the last quarter. Finally, Pointe Capital Management LLC increased its stake in Pfizer by 2.2% in the third quarter. Pointe Capital Management LLC now owns 10,672 shares of the biopharmaceutical company’s stock valued at $459,000 after acquiring an additional 229 shares during the last quarter. 64.99% of the stock is currently owned by hedge funds and other institutional investors.
About Pfizer
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.